Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab dosing frequency in moderate to severe plaque psoriasis ≥90 kg
2015-004620-60Phase 3Completed
- Sponsor
- Novartis
- Start
- Mar 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of secukinumab in psoriasis and plaque psoriasis (2 arms), sponsored by Novartis. Primary endpoint: PASI 90. Started Mar 2018; status: completed.
02
Drugs
secukinumab
03
Conditions
psoriasisplaque psoriasis
Beyond the preview
Go deeper on 2015-004620-60.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004620-60.